MS4A1 and B-cell non-Hodgkin lymphoma: [6] Currently, there are two approved RIT agents for use in B cell lymphoma: 131 I-tositumomab (Bexxar®; GSK) and 90 Y-ibritumomab tiuxetan (90Y-IT) Zevalin®; Spectrum pharmaceuticals), both targeting CD20.